Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Drug Data Expected To Be Available For Research Dec. 1

Executive Summary

CMS is targeting Dec. 1 as the date for opening Medicare Part D drug claims data to both government and independent researchers

You may also be interested in...



FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative

FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.

FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative

FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.

Group With Ties To Daschle Urges Release Of More Detailed Part D Data

A new report from the Center for American Progress highlights the potential value to comparative effectiveness research of Medicare Part D claims and performance data and urges the release of more detailed information on the program through administrative changes

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel